56.75
price up icon1.58%   0.88
after-market After Hours: 56.94 0.19 +0.33%
loading
Revolution Medicines Inc stock is traded at $56.75, with a volume of 2.46M. It is up +1.58% in the last 24 hours and up +19.93% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$55.87
Open:
$55.62
24h Volume:
2.46M
Relative Volume:
2.33
Market Cap:
$9.32B
Revenue:
$29.52M
Net Income/Loss:
$-484.27M
P/E Ratio:
-17.41
EPS:
-3.26
Net Cash Flow:
$-457.88M
1W Performance:
+12.55%
1M Performance:
+19.93%
6M Performance:
+41.17%
1Y Performance:
+156.09%
1-Day Range:
Value
$54.97
$56.91
1-Week Range:
Value
$49.92
$56.91
52-Week Range:
Value
$18.79
$56.91

Revolution Medicines Inc Stock (RVMD) Company Profile

Name
Name
Revolution Medicines Inc
Name
Phone
415-766-3638
Name
Address
700 SAGINAW DR, REDWOOD CITY, CA
Name
Employee
443
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RVMD's Discussions on Twitter

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-16-24 Reiterated Needham Buy
Jul-12-24 Initiated Barclays Overweight
Jul-08-24 Initiated Jefferies Buy
Apr-12-24 Reiterated Needham Buy
Apr-10-24 Upgrade Raymond James Outperform → Strong Buy
Mar-11-24 Initiated Piper Sandler Overweight
Jan-05-24 Upgrade BofA Securities Neutral → Buy
Jan-04-24 Initiated Wedbush Outperform
Nov-16-23 Initiated Raymond James Outperform
Feb-28-23 Upgrade JP Morgan Neutral → Overweight
Dec-14-22 Initiated Needham Buy
Oct-21-22 Initiated Oppenheimer Outperform
May-20-22 Initiated BofA Securities Neutral
Mar-01-22 Upgrade Stifel Hold → Buy
Sep-23-21 Initiated Stifel Hold
Aug-12-21 Downgrade Goldman Buy → Neutral
May-18-21 Initiated Goldman Buy
May-21-20 Initiated H.C. Wainwright Buy
Mar-09-20 Initiated Cowen Outperform
Mar-09-20 Initiated Guggenheim Buy
Mar-09-20 Initiated JP Morgan Neutral
View All

Revolution Medicines Inc Stock (RVMD) Latest News

pulisher
05:16 AM

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat

05:16 AM
pulisher
09:11 AM

Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times

09:11 AM
pulisher
08:26 AM

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com

08:26 AM
pulisher
04:46 AM

Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India

04:46 AM
pulisher
03:40 AM

Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com UK

03:40 AM
pulisher
01:51 AM

Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada

01:51 AM
pulisher
Nov 01, 2024

Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World

Nov 01, 2024
pulisher
Oct 31, 2024

Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

Revolution Medicines stock hits 52-week high at $51.01 - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com UK

Oct 30, 2024
pulisher
Oct 30, 2024

Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace

Oct 28, 2024
pulisher
Oct 26, 2024

Revolution Medicines reports positive RMC-9805 study results - Investing.com India

Oct 26, 2024
pulisher
Oct 25, 2024

Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - The Manila Times

Oct 25, 2024
pulisher
Oct 25, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with - The Bakersfield Californian

Oct 25, 2024
pulisher
Oct 25, 2024

Revolution Medicines Presents Initial Data from RMC-9805 - GlobeNewswire

Oct 25, 2024
pulisher
Oct 24, 2024

Needham & Company LLC Reaffirms Buy Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

(RVMD) On The My Stocks Page - Stock Traders Daily

Oct 24, 2024
pulisher
Oct 23, 2024

Revolution Medicines reports progress in pancreatic cancer study By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Revolution Medicines (NASDAQ:RVMD) Shares Up 3.2%Still a Buy? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Revolution Medicines reports progress in pancreatic cancer study - Investing.com India

Oct 23, 2024
pulisher
Oct 23, 2024

Revolution Medicines Presents Updated Data from RMC-6236 - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Head to Head Comparison: Revolution Medicines (NASDAQ:RVMD) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World

Oct 23, 2024
pulisher
Oct 21, 2024

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma - BioSpace

Oct 21, 2024
pulisher
Oct 21, 2024

Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire

Oct 21, 2024
pulisher
Oct 19, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Oct 19, 2024
pulisher
Oct 17, 2024

Revolution Medicines executive sells $824,804 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Revolution Medicines executive sells $824,804 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 16, 2024

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighTime to Buy? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 16,666 Shares of Stock - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Revolution Medicines COO Margaret Horn sells $2.52m in stock - Investing.com India

Oct 16, 2024
pulisher
Oct 16, 2024

Revolution Medicines COO Margaret Horn sells $2.52m in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Revolution Medicines CEO sells $1.51 million in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 15, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 6,000 Shares - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Revolution Medicines CFO Jack Anders sells shares worth $502,979 - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

Revolution Medicines CFO Jack Anders sells shares worth $502,979 By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

Revolution Medicines' general counsel sells $301,026 in stock By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

Revolution Medicines CEO sells $1.51 million in stock - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

Revolution Medicines' general counsel sells $301,026 in stock - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

AQR Capital Management LLC Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Check Out Revolution Medicines Inc (RVMD)’s Trade Data Rather Than the Analysts’ Views - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

An Analysis of Revolution Medicines Inc (RVMD)’s Potential Price Growth - Knox Daily

Oct 14, 2024
pulisher
Oct 13, 2024

Trend Tracker for (RVMD) - Stock Traders Daily

Oct 13, 2024

Revolution Medicines Inc Stock (RVMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):